Braftovi 50 mg Hard Capsules: Uses, Side Effects & Leaflet
Quick summary Braftovi 50 mg hard capsules contain encorafenib, a prescription cancer medicine used for certain adults with BRAF V600-mutated cancers. It is taken by mouth and is often used with other medicines. Always...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Braftovi 50 mg hard capsules contain encorafenib, a prescription cancer medicine used for certain adults with BRAF V600-mutated cancers. It is taken by mouth and is often used with other medicines. Always follow the patient leaflet and your oncology team’s instructions.
Medical disclaimer: This article is for general information only and does not replace advice from a doctor, pharmacist, or the official patient information leaflet. Cancer treatment is individualised, and only your healthcare team can confirm whether a medicine is appropriate for you.
What are Braftovi 50 mg hard capsules?
Braftovi is the brand name for encorafenib. It is a prescription medicine supplied as 50 mg hard capsules.
It is used in adults with certain cancers that have a specific BRAF V600 mutation. This makes it a targeted treatment rather than a general cancer medicine.
What is Braftovi used for?
Based on the original content, Braftovi is used for two main cancer types:
- Unresectable or metastatic melanoma with a BRAF V600 mutation, typically in combination with binimetinib.
- Metastatic colorectal cancer with a BRAF V600E mutation, often used with cetuximab.
These uses depend on the cancer type and the presence of the relevant mutation. Your specialist team will confirm whether testing has shown the mutation needed for treatment.
How does Braftovi work?
Braftovi works by selectively inhibiting BRAF kinase, which is part of the MAPK signalling pathway involved in cell growth. In cancers with a BRAF mutation, this pathway may be overactive.
By targeting this mutation, Braftovi is intended to help slow cancer progression. In practice, it is often used as part of a combination treatment plan.
How is Braftovi taken?
Braftovi is taken orally as hard capsules. The original content states that it is usually taken once daily, with or without food.
Because cancer treatment plans vary, the exact schedule should always come from the prescribing clinician and the official leaflet.
What dosage information is available?
The original content gives the following starting doses:
- Melanoma: 450 mg per day
- Colorectal cancer: 300 mg per day
These are starting doses mentioned in the source content. Dose changes may be needed during treatment, so patients should rely on their own prescription and treatment plan rather than general summaries.
What side effects are mentioned?
The original content lists the following potential side effects:
- Fatigue
- Nausea and vomiting
- Skin rash and photosensitivity
- Left ventricular dysfunction
- Ocular toxicity
Not everyone will experience these effects, and this is not a complete list. The patient leaflet and healthcare team should be checked for the full safety information relevant to the individual treatment plan.
Why is Braftovi used with other medicines?
Braftovi is often used in combination therapy.
With binimetinib
For BRAF-mutated melanoma, the original content states that Braftovi is commonly used with binimetinib.
With cetuximab
For BRAF V600E-mutated metastatic colorectal cancer, it is often used with cetuximab.
Combination treatment is part of the prescribed cancer plan and should only be managed by the treating oncology team.
What should patients check in the patient information leaflet?
The patient information leaflet can help explain:
- How to take the capsules
- What to do if a dose is missed
- Storage instructions
- Possible side effects
- When to seek medical advice
If anything in the leaflet is unclear, a pharmacist or oncology nurse can help interpret it.
Frequently asked questions
▸ Is Braftovi a chemotherapy medicine?
No. The original content describes Braftovi as a targeted therapy that inhibits BRAF in cancer cells, rather than a traditional chemotherapy medicine.
▸ What cancers is Braftovi used for?
The source content says it is used for unresectable or metastatic melanoma with a BRAF V600 mutation and metastatic colorectal cancer with a BRAF V600E mutation.
▸ How is Braftovi taken?
It is taken by mouth as hard capsules. The original content says it is usually taken once daily, with or without food.
▸ What side effects are mentioned in the article?
The article mentions fatigue, nausea and vomiting, skin rash and photosensitivity, left ventricular dysfunction, and ocular toxicity.
▸ Should the patient leaflet be read carefully?
Yes. The leaflet is an important source for practical instructions, safety information, and what to do if questions come up during treatment.
Safety reminder: If you are taking Braftovi or have been prescribed it, contact your oncology team or pharmacist promptly about any new or worsening symptoms, and use the official leaflet for treatment-specific instructions.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.